Search

Displaying results 6951 - 6960 of 9333 in total
  1. Drug

    Risvodetinib

    go.drugbank.com/drugs/DB21602
    Investigational

    The usage of the INN stem '-tinib' in the name indicates that Risvodetinib is a tyrosine kinase inhibitor.

  2. Drug

    Milveterol

    go.drugbank.com/drugs/DB05043
    Investigational

    GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

  3. Drug

    Ethyl pyruvate

    go.drugbank.com/drugs/DB05869
    Investigational

    CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions.

  4. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment

  5. Drug

    alpha-N-Acetyl-D-galactosamine

    go.drugbank.com/drugs/DB03567
    Investigational

    The N-acetyl derivative of galactosamine. [PubChem]

    Synonyms: Tn saccharide, Tn antigen saccharide
  6. Drug

    D-Aspartic Acid

    go.drugbank.com/drugs/DB02655
    Investigational

    The D-isomer of aspartic acid. [PubChem]

  7. Drug

    Biropepimut-S

    go.drugbank.com/drugs/DB14816
    Investigational

    Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral

  8. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide. … It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.

  9. Drug

    AMY-101

    go.drugbank.com/drugs/DB14803
    Investigational

    AMY-101, also known as compstatin 40, is a peptidic inhibitor of the central complement component C3. … AMY-101 is under investigation in clinical trial NCT03694444 (A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis).

  10. Drug

    SRP-9005

    go.drugbank.com/drugs/DB17958
    Investigational

    Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.[A260142]